Radius Health (NASDAQ:RDUS)inks agreement to acquire the global development and commercialization rights to Benuvia Therapeutics' synthetic cannabidiol oral solution (RAD011).

美国Radius Health公司同意获得Benuvia Therapeutics公司合成大麻二酚口服溶液(RAD011)的全球开发和商业化权利。

The Company plans to initiate a Phase 2/3 study for patients with Prader-Willi syndrome (PWS) in H2 2021 pending regulatory discussion with the FDA.

该公司计划在2021年H2启动普瑞德-威利综合征(PWS)患者的2/3期研究，目前正在与FDA进行监管讨论。

Under the terms of agreement, Radius acquired RAD011 for $12.5M, with an additional $15M in milestone payments. For the next three indications, the Company may pay up to $45M in development milestones and a tiered, high single-digit effective royalty.

根据协议条款，Radius公司以1250万美元的价格收购了RAD011，并追加了1500万美元的里程碑付款。对于接下来的三个指标，该公司可能会支付高达4500万美元的开发里程碑费用，以及一种分层的、高个位数的有效版税。

PWS is a complex genetic disorder with clinical manifestations on the endocrine and neurological systems.

PWS是一种复杂的遗传疾病，临床表现为内分泌和神经系统。

Radius will host a conference call today at 8:15 a.m. ET to review the transaction.

Radius将于美国东部时间今天上午8点15分召开电话会议，审查交易。